This trial demonstrated that 77% of subjects treated with Calquence and venetoclax combo and 83% of those who received the therapy along with venetoclax and obinutuzumab remained progression-free ...

PFE's new drug launches and Seagen acquisition are driving revenue gains despite COVID declines and market headwinds.

AstraZeneca’s share price has fallen a lot from its September high, but this could mean a tremendous opportunity for me to ...

AstraZeneca has received another boost to its aspirations in oncology with the FDA approval of Calquence, a next generation treatment for mantle cell lymphoma (MCL). Calquence (acalabrutinib ...

AstraZeneca's Calquence has hit the mark in the phase 3 AMPLIFY trial in chronic lymphocytic leukaemia (CLL), a study that chief executive Pascal Soriot recently said could be a "blockbuster ...

Real-world data show no significant differences in overall survival between patients with or without cytogenetic risk factors ...

During a live event, Danielle M. Brander, MD, discussed use of zanubrutinib in high-risk chronic lymphocytic leukemia.

AstraZeneca’s Calquence approval decision follows a positive opinion from the Committee for Medicinal Products for Human Use. Credit: Elzbieta Krzysztof/Shutterstock. The European Commission (EC) has ...